Latest Soleus Capital Management, L.P. Stock Portfolio

$1.13Billion– No. of Holdings #92

Soleus Capital Management, L.P. Performance:

2024 Q2: -4.33%YTD: 6.46%2023: 9.22%

Performance for 2024 Q2 is -4.33%, and YTD is 6.46%, and 2023 is 9.22%.

About Soleus Capital Management, L.P. and 13F Hedge Fund Stock Holdings

In it's latest 13F Holdings report, Soleus Capital Management, L.P. reported an equity portfolio of $1.1 Billions as of 30 Jun, 2024.

The top stock holdings of Soleus Capital Management, L.P. are TGTX, IOVA, UTHR. The fund has invested 5.7% of it's portfolio in TG THERAPEUTICS INC and 5.3% of portfolio in IOVANCE BIOTHERAPEUTICS INC.

The fund managers got completely rid off HCA HEALTHCARE INC (HCA), BIOGEN INC (BIIB) and RIGEL PHARMACEUTICALS INC (RIGL) stocks. They significantly reduced their stock positions in NATERA INC (NTRA), GENEDX HOLDINGS CORP (SMFR) and BICYCLE THERAPEUTICS PLC (BCYC). Soleus Capital Management, L.P. opened new stock positions in TERNS PHARMACEUTICALS INC (TERN), ENLIVEN THERAPEUTICS INC and ALNYLAM PHARMACEUTICALS INC (ALNY). The fund showed a lot of confidence in some stocks as they added substantially to PRAXIS PRECISION MEDICINES I (PRAX), CVRX INC (CVRX) and THE BEAUTY HEALTH COMPANY (SKIN).

Soleus Capital Management, L.P. Equity Portfolio Value

Last Reported on: 14 Aug, 2024

Soleus Capital Management, L.P. Annual Return Estimates Vs S&P 500

Our best estimate is that Soleus Capital Management, L.P. made a return of -4.33% in the last quarter. In trailing 12 months, it's portfolio return was 16.41%.

New Buys

Ticker	$ Bought
terns pharmaceuticals inc	33,694,100
enliven therapeutics inc	17,977,700
alnylam pharmaceuticals inc	17,423,100
10x genomics inc	13,984,600
alector inc	10,165,100
biodesix inc	9,351,300
orthopediatrics corp	8,901,220
rigel pharmaceuticals inc	8,579,190

New stocks bought by Soleus Capital Management, L.P.

Additions

Ticker	% Inc.
praxis precision medicines i	1,330
cvrx inc	1,110
the beauty health company	843
evolus inc	620
avita medical inc	256
syndax pharmaceuticals inc	123
iovance biotherapeutics inc	115
cg oncology inc	94.88

Additions to existing portfolio by Soleus Capital Management, L.P.

Reductions

Ticker	% Reduced
natera inc	-95.86
genedx holdings corp	-88.89
bicycle therapeutics plc	-84.64
novocure ltd	-84.35
teva pharmaceutical inds ltd	-83.18
iradimed corp	-71.78
olema pharmaceuticals inc	-67.1
janux therapeutics inc	-64.83

Soleus Capital Management, L.P. reduced stake in above stock

Sold off

Ticker	$ Sold
regulus therapeutics inc	-4,500,000
mannkind corp	-7,060,170
taysha gene therapies inc	-2,654,750
rigel pharmaceuticals inc	-13,678,100
mind medicine mindmed inc	-7,052,230
compass pathways plc	-4,705,380
kalvista pharmaceuticals inc	-4,577,960
nkarta inc	-3,243,000

Soleus Capital Management, L.P. got rid off the above stocks

Sector Distribution

Soleus Capital Management, L.P. has about 87.5% of it's holdings in Healthcare sector.

Sector	%
Healthcare	87.5
Others	11.4

Market Cap. Distribution

Soleus Capital Management, L.P. has about 10.8% of it's portfolio invested in the large-cap and mega-cap stocks.

Category	%
SMALL-CAP	33.1
MID-CAP	32.2
MICRO-CAP	11.9
UNALLOCATED	11.8
LARGE-CAP	9.1
MEGA-CAP	1.7

Stocks belong to which Index?

About 59.7% of the stocks held by Soleus Capital Management, L.P. either belong to S&P 500 or RUSSELL 2000 index.

Index	%
RUSSELL 2000	57.9
Others	40.3
S&P 500	1.8

Top 5 Winners (%)		%
RIGL	rigel pharmaceuticals inc	754.2 %
SMFR	genedx holdings corp	127.8 %
ALNY	alnylam pharmaceuticals inc	62.1 %
INSM	insmed inc	59.1 %
SRDX	surmodics inc	42.6 %

Top 5 Winners ($)		$
UTHR	united therapeutics corp del	17.2 M
NRIX	nurix therapeutics inc	12.2 M
SRDX	surmodics inc	10.0 M
SMFR	genedx holdings corp	9.1 M
TGTX	tg therapeutics inc	8.9 M

Top 5 Losers (%)		%
VSTM	verastem inc	-74.4 %
BCAB	bioatla inc	-59.2 %
FATE	fate therapeutics inc	-55.3 %
XFOR	x4 pharmaceuticals inc	-54.5 %
NPCE	neuropace inc	-42.7 %

Top 5 Losers ($)		$
IOVA	iovance biotherapeutics inc	-34.3 M
VSTM	verastem inc	-14.4 M
NPCE	neuropace inc	-13.7 M
CCCC	c4 therapeutics inc	-10.8 M
CELC	celcuity inc	-9.2 M

Soleus Capital Management, L.P. Holdings Map

This heatmap illustrates the top 50 positions within the fund's portfolio.

Current Stock Holdings of Soleus Capital Management, L.P.

Soleus Capital Management, L.P. has 92 stocks in it's portfolio. About 36.5% of the portfolio is in top 10 stocks. IOVA proved to be the most loss making stock for the portfolio. UTHR was the most profitable stock for Soleus Capital Management, L.P. last quarter.

Last Reported on: 14 Aug, 2024

Ticker	Namesorted ascending	% Portfolio	Shares Held	$ Value	Type	% Change
AADI	aadi bioscience inc	0.04	333,227	486,511	new

ACLX	arcellx inc	0.83	170,741	9,423,200	added	13.83

ADPT	adaptive biotechnologies cor	0.55	1,720,000	6,226,400	new

ADVM	adverum biotechnologies inc	0.09	147,246	1,010,110	new

ALEC	alector inc	0.90	2,239,010	10,165,100	new

ALNY	alnylam pharmaceuticals inc	1.54	71,700	17,423,100	new

ANNX	annexon inc	0.00	0.00	0.00	sold off	-100

APLT	applied therapeutics inc	0.52	1,269,710	5,929,560	reduced	-18.86

ARQT	arcutis biotherapeutics inc	0.00	0.00	0.00	sold off	-100

AXGN	axogen inc	2.11	3,305,820	23,934,100	added	6.44

BCAB	bioatla inc	0.47	3,901,310	5,344,800	reduced	-4.03

BCYC	bicycle therapeutics plc	0.04	23,500	475,640	reduced	-84.64

BDSX	biodesix inc	0.82	6,111,960	9,351,300	new

BGNE	beigene ltd	1.73	137,700	19,645,700	reduced	-7.02

BHC	bausch health cos inc	0.74	1,206,000	8,405,820	added	80.00

BIIB	biogen inc	0.00	0.00	0.00	sold off	-100

CCCC	c4 therapeutics inc	1.65	4,052,000	18,720,200	added	64.78

CELC	celcuity inc	1.75	1,211,190	19,839,200	reduced	-30.04

CMPS	compass pathways plc	0.00	0.00	0.00	sold off	-100

CSTL	castle biosciences inc	1.64	853,628	18,583,500	added	17.67